Heart Failure

Tirzepatide reduced the risk of heart failure hospitalization or cardiovascular death by 38% and improved body weight by up to 21% in the SUMMIT trial.

In part 3 of this 5-part series, Lerma discusses recent updates in the management of chronic kidney disease in people with type 2 diabetes.

In part 2 of this 5-part series, Lerma and Lala-Trindade discuss the key differences in MoA for nsMRA and MRAs.

In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

New FINEARTS-HF data shows that finerenone reduces albuminuria in patients with HFmrEF or HFpEF, but without significant eGFR changes.

Masri previewed data to be presented at the AHA 2024 Scientific Sessions and shared his excitement for the ongoing phase 3 trial of NTLA-2001.

Anemia could be a reliable sign of all-cause mortality in patients with heart failure.

The sNDA submission to the FDA included a Priority Review Voucher, which commits the regulatory agency to an accelerated review timeline.

Optimal use of GDMT therapy in heart failure could save an estimated 1.19 million lives globally over the course of 1 year.

Anemia is frequently observed in primary care patients with HF and is linked to worse prognosis and comorbidities, including cancer.

The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!

EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.

Deepak Bhatt, MD, MPH, MBA, discusses the results of a prespecified analysis of the EMPACT-MI trial examining the effect across the spectrum of baseline kidney function.

The endocrinology month in review for August 2024 spotlights 6 pieces of major pipeline news or regulatory announcements as well as multiple episodes of Diabetes Dialogue.

The August 2024 cardiology month in review highlights critical data from the European Society of Cardiology Congress 24 and the latest updates on finerenone.

Deepak Bhatt, MD, MPH, MBA, discusses a group of 4 high-impact studies from ESC Congress 2024: FINEARTS-HF, ABYSS, RESHAPE-HF2, and SHAM-PVI.

Ahmad Masri, MD, MS, highlights a trio of studies from ESC Congress 2024 examining use of aficamten in hypertrophic cardiomyopathy.

Ahmad Masri, MD, MS, discusses the results of a SEQUOIA-HCM substudy leveraging cardiac magnetic resonance to assess structural changes associated with aficamten use in HCM.

Ahmad Masri, MD, MS, discusses an integrated safety analysis of aficamten using data from 3 clinical trials.

EMPACT-MI study shows empagliflozin is safe post-acute MI and reduces heart failure events, with kidney protection across kidney function levels.

MAVA-LTE trial data show mavacamten's sustained benefits in symptomatic obstructive HCM, with long-term improvements in LVOT, NT-proBNP, and quality of life.

A meta-analysis shows GLP-1 RAs and SGLT2 inhibitors offer distinct cardiovascular and kidney benefits in type 2 diabetes.

FINEARTS-HF results suggest finerenone may join SGLT2 inhibitors as a second pillar in treating HFmrEF/HFpEF, cutting total heart failure events by 16%.

Rahul Aggarwal, MD, discusses the findings of a SCORED analysis examining sotagliflozin's effects based on diabetes duration.

RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.

People with the most weekend catch-up sleep had a 20% lower risk of heart disease, especially those who were sleep-deprived during the week.

HELIOS-B trial shows vutrisiran reduces all-cause mortality and CV events in ATTR-CM, with benefits consistent regardless of tafamidis use.

The ABYSS trial suggests no clear benefit of continuing beta-blockers post-MI in patients with preserved LVEF, echoing REDUCE-AMI findings.

Allegheny Health Network (AHN) implants innovative device to manage central sleep apnea in heart failure patients, reducing mortality rise and improving quality of life.